The nomogram also exhibited excellent discriminative ability for predicting a composite PHT endpoint (AUC: 0.821, <i>p</i> = 0.417).<h4>Conclusion</h4>We developed a validated nomogram that incorporates the baseline CONUT score and key clinical variables (e.g., tumor burden, ferritin, IFN-γ) to effectively predict PHT risk in R/R MM patients after CAR-T cell therapy, thereby facilitating early risk stratification and guiding personalized management. This evidence concerns the gene IFNG and neoplasm.